Haleon plc filed a Form 6-K on November 2, 2026, disclosing a UK Market Abuse Regulation notification that Independent Non-Executive Director Bláthnaid Bergin purchased 7,670 ordinary shares in the company on October 30, 2026.

Key Highlights

  • Buyer: Bláthnaid Bergin, identified in the filing as an Independent Non-Executive Director and Person Discharging Managerial Responsibilities (PDMR).
  • Transaction: Purchase of 7,670 ordinary shares of Haleon plc (identification code GB00BMX86B70).
  • Price: £3.242 per share, described as a single transaction with no aggregation.
  • Transaction date: October 30, 2026, on the London Stock Exchange (XLON).
  • Notification received: The company reported receiving the notification on October 30, 2026.
  • Listing: Haleon is listed on LSE/NYSE:HLN, as stated in the filing.

Haleon Discloses PDMR Share Purchase by Director Bláthnaid Bergin

According to the Form 6-K filed with the U.S. Securities and Exchange Commission, Haleon plc (LSE/NYSE:HLN) announced a director shareholding notification on November 2, 2026, in line with the requirements of the UK Market Abuse Regulation. The filing states that on October 30, 2026, the company received notification of a transaction by Bláthnaid Bergin, who holds the position of Independent Non-Executive Director and is classified as a PDMR under the applicable regulation.

The filing discloses that Bergin purchased 7,670 ordinary shares in Haleon plc at a price of £3.242 per share on October 30, 2026. The transaction was executed on the London Stock Exchange (XLON) and is described in the filing as a single transaction, with no aggregated volume or blended price to report. The shares carry the identification code GB00BMX86B70. The filing was signed by Amanda Mellor, Company Secretary, on behalf of Haleon plc.

Haleon describes itself in the filing as "a consumer company that is solely focused on better everyday health," with a product portfolio spanning six major categories including Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other. The company notes that its brands include Advil, Centrum, Panadol, Sensodyne, and Voltaren, among others.

What Was Disclosed

Haleon plc filed a 6-K reporting that Independent Non-Executive Director Bláthnaid Bergin purchased 7,670 ordinary shares at £3.242 each on October 30, 2026, on the London Stock Exchange, pursuant to UK Market Abuse Regulation disclosure requirements.